An outlook on biomarkers in cardiogenic shock.
Journal
Current opinion in critical care
ISSN: 1531-7072
Titre abrégé: Curr Opin Crit Care
Pays: United States
ID NLM: 9504454
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
pubmed:
27
5
2020
medline:
1
12
2020
entrez:
27
5
2020
Statut:
ppublish
Résumé
Cardiogenic shock is a severe complication with mortality rates of ∼50% that requires a rapid and complex management to aid and identify the highest and lowest risk patients. To that end, novel cardiogenic shock biomarkers are needed to improve risk stratification and to personalize therapy. Established biomarkers such as BNP, NT-proBNP, ST2, and troponins provide insufficient predictive value in cardiogenic shock. More recent biomarkers, including DPP3, adrenomedullin, angiopoietin 2, and the CS4P score are gaining momentum. DPP3 showed early prediction of refractory status and survival in cardiogenic shock. The CS4P score is based on the levels of liver fatty acid-binding protein (L-FABP), beta-2-microglobulin (B2M), fructose-bisphosphate aldolase B (ALDOB), and SerpinG1 (IC1). These proteins are not cardiac-specific but reflect multiorgan dysfunction, systemic inflammation, and immune activation. The CS4P improved reclassification of 32% of patients compared with the CardShock risk score. A new wave of research focused on novel proteomic and molecular techniques, is providing new candidates that promise to aid clinical decision-making and patient stratification in cardiogenic shock. The CS4P score is emerging as the most robust, yet it requires prospective validation in cardiogenic shock patients managed with circulatory and ventricular assist devices.
Identifiants
pubmed: 32452847
doi: 10.1097/MCC.0000000000000739
pii: 00075198-202008000-00012
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
392-397Références
Ahmad T, Fiuzat M, Pencina MJ, et al. Charting a roadmap for heart failure biomarker studies. JACC Heart Fail 2014; 2:477–488.
van Diepen S, Katz JN, Albert NM, et al. American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Mission: LifelineContemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association. Circulation 2017; 136:e232–e268.
Mandawat A, Rao SV. Percutaneous mechanical circulatory support devices in cardiogenic shock. Circ Cardiovasc Interv 2017; 10: pii: e004337.
pii: e004337
Iborra-Egea O, Rueda F, García-García C, et al. Molecular signature of cardiogenic shock. Eur Heart J 2019; pii: ehz783 [Epub ahead of print].
pii: ehz783
Thygesen K, Alpert JS, Jaffe AS, et al. ESC Scientific Document GroupForth Universal Definition of Myocardial Infarction (2018). Eur Heart J 2019; 40:237–269.
Amsterdam E, Wenger N, Brindis R, et al. ACC/AHA Task Force Members; Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons2014 ACC/AHA guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 130:2354–2394.
Bhatt DL, Roe MT, Peterson ED, et al. CRUSADE InvestigatorsUtilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA 2004; 292:2096–2104.
de Antonio M, Lupón J, Galán A, et al. Head-to-head comparison of high-sensitivity troponin T and sensitive-contemporary troponin I regarding heart failure risk stratification. Clin Chim Acta 2013; 426:18–24.
Jia X, Sun W, Hoogeveen RC, et al. High-sensitivity troponin I and incident coronary events, stroke, heart failure hospitalization, and mortality in the ARIC Study. Circulation 2019; 139:2642–2653.
Duchnowski P, Hryniewiecki T, Kuśmierczyk M, Szymański P. High-sensitivity troponin T predicts postoperative cardiogenic shock requiring mechanical circulatory support in patients with valve disease. Shock 2019; 53:175–178.
Kociol RD, Pang PS, et al. Troponin elevation in heart failure. J Am Coll Cardiol 2010; 56:1071–1078.
Jolly SS, Shenkman H, Brieger D, et al. GRACE InvestigatorsQuantitative troponin and death, cardiogenic shock, cardiac arrest and new heart failure in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS): insights from the Global Registry of Acute Coronary Events. Heart 2011; 97:197–202.
De Backer D, Biston P, Devriendt J, et al. SOAP II InvestigatorsComparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010; 362:779–789.
Januzzi JL, Bayes-Genis A. Evolution of amino-terminal pro-B type natriuretic peptide testing in heart failure. Drug News Perspect 2009; 22:267–273.
Mueller C, McDonald K, de Boer RA, et al. Heart Failure Association of the European Society of CardiologyHeart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail 2019; 21:715–731.
Prondzinsky R, Lemm H, Swyter M, et al. Intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: The prospective, randomized IABP SHOCK Trial for attenuation of multiorgan dysfunction syndrome. Crit Care Med 2010; 38:152–160.
Bal L, Thierry S, Brocas E, et al. B-type natriuretic peptide (BNP) and N-terminal-proBNP for heart failure diagnosis in shock or acute respiratory distress. Acta Anaesthesiol Scand 2006; 50:340–347.
Pruszczyk P. N-terminal pro-brain natriuretic peptide as an indicator of right ventricular dysfunction. J Card Fail 2005; 11: (5 Suppl): S65–S69.
Januzzi J, Morss A, Tung R, et al. Natriuretic peptide testing for the evaluation of critically ill patients with shock in the intensive care unit: a prospective cohort study. Crit Care 2006; 10:R37.
Lemm H, Prondzinsky R, Geppert A, et al. BNP and NT-proBNP in patients with acute myocardial infarction complicated by cardiogenic shock: results from the IABP Shock trial. Crit Care 2010; 14: (Suppl 1): 146.
Luyt CE, Landivier A, Leprince P, et al. Usefulness of cardiac biomarkers to predict cardiac recovery in patients on extracorporeal membrane oxygenation support for refractory cardiogenic shock. J Crit Care 2012; 27:524.e7–524.e14.
Jarai R, Fellner B, Haoula D, et al. Early assessment of outcome in cardiogenic shock: relevance of plasma N-terminal pro-B-type natriuretic peptide and interleukin-6 levels. Crit Care Med 2009; 37:1837–1844.
Daniels LB, Bayes-Genis A. Using ST2 in cardiovascular patients: a review. Future Cardiol 2014; 10:525–539.
Bayés-Genís A, Núñez J, Lupón J. Soluble ST2 for prognosis and monitoring in heart failure. J Am Coll Cardiol 2017; 70:2389–2392.
Bayés-Genís A, Núñez J, Lupón J. Soluble ST2 for prognosis and monitoring in heart failure: the new gold standard? J Am Coll Cardiol 2017; 70:2389–2392.
Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 2017; 70:776–803.
Bayes-Genis A, Zamora E, de Antonio M, et al. Soluble ST2 serum concentration and renal function in heart failure. J Card Fail 2013; 19:768–775.
Parenica J, Malaska J, Jarkovsky J, et al. Soluble ST2 levels in patients with cardiogenic and septic shock are not predictors of mortality. Exp Clin Cardiol 2012; 17:205–209.
Tolppanen H, Rivas-Lasarte M, Lassus J, et al. CardShock InvestigatorsCombined measurement of soluble ST2 and amino-terminal pro-B-type natriuretic peptide provides early assessment of severity in cardiogenic shock complicating acute coronary syndrome. Crit Care Med 2017; 45:e666–e673.
Tolppanen H, Lasarte MR, Lassus J, et al. Combined NT-proBNP and ST2 measurement has powerful prognostic value in cardiogenic shock caused by acute coronary syndrome. J Am Coll Cardiol 2016; 67:492.
Ocaranza MP, Jalil JE. On endogenous angiotensin II antagonism in hypertension. Hypertension 2016; 68:552–554.
Prajapati SC, Chauhan SS. Dipeptidyl peptidase III: a multifaceted oligopeptide N-end cutter. FEBS J 2011; 278:3256–3276.
Rehfeld L, Funk E, Jha S, et al. Novel methods for the quantification of dipeptidyl peptidase 3 (DPP3) concentration and activity in human blood samples. J Appl Lab Med 2019; 3:943–953.
Deniau B, Rehfeld L, Santos K, et al. Circulating dipeptidyl peptidase 3 is a myocardial depressant factor: dipeptidyl peptidase 3 inhibition rapidly and sustainably improves haemodynamics. Eur J Heart Fail 2019; 22:290–299.
Takagi K, Blet A, Levy B, et al. Circulating dipeptidyl peptidase 3 and alteration in haemodynamics in cardiogenic shock: results from the OptimaCC trial. Eur J Heart Fail 2020; 22:279–286.
Katayama T, Nakashima H, Takagi C, et al. Predictors of mortality in patients with acute myocardial infarction and cardiogenic shock. Circ J 2005; 69:83–88.
Tolppanen H, Rivas-Lasarte M, Lassus J, et al. Adrenomedullin: a marker of impaired hemodynamics, organ dysfunction, and poor prognosis in cardiogenic shock. Ann Intensive Care 2017; 7:6.
Link A, Pöss J, Rbah R, et al. Circulating angiopoietins and cardiovascular mortality in cardiogenic shock. Eur Heart J 2013; 34:1651–1662.
Pöss J, Fuernau G, Denks D, et al. Angiopoietin-2 in acute myocardial infarction complicated by cardiogenic shock-a biomarker substudy of the IABP-SHOCK II-Trial. Eur J Heart Fail 2015; 17:1152–1160.
Rueda F, Borràs E, García-García C, et al. Protein-based cardiogenic shock patient classifier. Eur Heart J 2019; 40:2684–2694.
Shah NR, Bieniarz MC, Basra SS, et al. Serum biomarkers in severe refractory cardiogenic shock. JACC Heart Fail 2013; 1:200–206.